Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Sandhya Madhuri Maddala currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single action is being handled by 1 distinct examiner, CHANG, KYUNG SOOK. Because there is only 1 pending office action in the entire portfolio, CHANG, KYUNG SOOK is designated as the busiest examiner with 1 pending case.
The prosecution is concentrated within 1 distinct art unit. This indicates a highly focused examination path where the company's current legal activity is confined to a single technical classification and a single individual at the patent office. For practitioners, this means that the immediate outcome of the portfolio's pending status depends entirely on the interactions with the assigned examiner in that specific art unit.
With 1 distinct examiner, there is no variance in the prosecution experience across the current portfolio. The Biotechnology & Pharmaceuticals classification provides the technical context for the active matter. Future filings would be required to see if the company expands beyond this 1 distinct art unit or continues to work with the same examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHANG, KYUNG SOOK | 1 | 60.4% | +40.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18096046 | FLOATING SUSTAINED RELEASE TABLET FORMULATION OF DROXIDOPA AND METHOD THEREOF | CHANG, KYUNG SOOK | 33d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18096046 | FLOATING SUSTAINED RELEASE TABLET FORMULATION OF DROXIDOPA AND METHOD THEREOF | CHANG, KYUNG SOOK | 33d |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18096046 | FLOATING SUSTAINED RELEASE TABLET FORMULATION OF DROXIDOPA AND METHOD THEREOF | CHANG, KYUNG SOOK | 1613 | §103§112 | Non-Final OA | 33d | Pending | Jan 12, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial